Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay (HBVQuant)

July 31, 2018 updated by: Hologic, Inc.

Collection of Plasma Samples From Individuals Initiating Therapy With Entecavir or Tenofovir for Chronic Hepatitis B Virus Infection for the Clinical Evaluation of the Aptima HBV Quant Assay

This non-interventional clinical study will be conducted to prospectively collect serial plasma samples from subjects with chronic HBV infection who are initiating antiviral therapy. These samples will be used to estimate clinical utility endpoints for the Aptima HBV Quant assay, which is used as an aid in the management of HBV-infected patients undergoing HBV antiviral therapy.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
331

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Kingswood, New South Wales, Australia, 2747
        • Napean Hospital, Gastroenterology and Hepatology Department
      • Sydney, New South Wales, Australia, 2170
        • Liverpool Hospital, Department of Gastroenterology
    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • St Vincent's Hospital Department of Gastroenterology
  • Bulgaria
      • PLeven, Bulgaria, 5800
        • UMHAT Dr. Gerogi Stranski, Clinic of Gastroenterology
      • Sofia, Bulgaria, 1431
        • UMHAT Aleksandrovska, Clinic of Gastroenterology
      • Sofia, Bulgaria, 1431
        • UMHAT Sveti Ivan Rilski Clinic of Gastroenterology
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
        • Foothills Medical Centre
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 2K5
        • GI Research Institute
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • University of British Columbia
      • Vancouver,, British Columbia, Canada, V5Z 1H2
        • Lair Centre
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • London Health Sciences Centre
      • Toronto, Ontario, Canada, M6H 3M1
        • Toronto Liver Centre
  • Germany
      • Berlin, Germany, 13353
        • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie
      • Berlin, Germany, 10969
        • Leberzentrum am Checkpoint Fachärztegemeinschaft für innere Krankheiten
      • Berlin, Germany, 13353
        • Zentrum für Infektiologie Berlin Prenzlauer Berg
      • Essen, Germany, 45122
        • Universitätsklinikum Essen Klinik für Gastroenterologie und Hepatologie
      • Hamburg, Germany, 20099
        • ifi-Studien und Projekte GmbH An der Asklepios Klinik St. Georg, Haus L
      • Hamburg, Germany, 20099
        • Ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg
      • Mainz, Germany, 55131
        • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
      • Mannheim, Germany, 68167
        • Universitätsmedizin Mannheim II. Medizinische Klinik
  • Hungary
      • Budapest, Hungary, 1125
        • Szent János Kórház
      • Budapest, Hungary
        • Szent János Kórház
      • Budapest, Hungary, 1097
        • Szent István és Szent László Kórház
      • Budapest, Hungary, 1111
        • Budai Hepatollógiai Központ
      • Budapest, Hungary
        • Budai Hepatollógiai Központ
      • Gyula, Hungary, 5700
        • Pándy Kálmán Megyei Kórház
  • Italy
      • Salerno, Italy
        • 'Ospdale Da Procida
      • Sassari, Italy
        • 'Medicina Interna - Ospedale Civile
      • Sassari, Italy
        • Medicina Interna - Ospedale Civile
  • New Zealand
    • Auckland
      • Grafton, Auckland, New Zealand, 1142
        • Auckland Liver Research Unit
    • Waikato
      • Hamilton West, Waikato, New Zealand, 3024
        • Waikato Gastroenterology and Respiratory Research Office
    • Wellington
      • Newton, Wellington, New Zealand, 6021
        • Gastroenterology Research, Wellington Hospital
  • Romania
    • Bucuresti
      • Sector 1, Bucuresti, Romania, 010825
        • Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila"
      • Sector 2, Bucuresti, Romania, 021105
        • Institutul de Boli Infectioase "Prof. Dr. Matei Bals"
      • Sector 2, Bucuresti, Romania
        • Institutul Clinic Fundeni, Bucuresti
      • Sector 5, Bucuresti, Romania
        • Spitalul Universitar de Urgență București
    • Jud. Sibiu
      • Sibiu, Jud. Sibiu, Romania
        • Spitalul Clinic Judetean de Urgenta Sibiu
    • Jud. Timis
      • Timisoara, Jud. Timis, Romania
        • Policlinica Algomed, Timisoara
    • Judetul Constanta
      • Constanta, Judetul Constanta, Romania
        • Spitalul Clininc de Boli Infecţioase Constanţa
  • Turkey
      • Ankara, Turkey, 06620
        • Ankara University School of Medicine
      • Ankara, Turkey
        • Yıldırım Beyazıt University Atatürk Training and Research Hospital
      • Aydin, Turkey, 09010
        • Adnan Menderes Üniversitesi
      • Bursa, Turkey, 16059
        • Uludag University School of Medicine
      • Diyarbakir, Turkey
        • Dicle University School of Medicine
      • Eskişehir, Turkey, 26040
        • Osmangazi University School of Medicine
      • Istanbul, Turkey, 34093
        • Istanbul University Istanbul School of Medicine
      • Izmir, Turkey, 35210
        • Dokuz Eylul University School of Medicine
      • Kocaeli, Turkey
        • Kocaeli University School of Medicine
      • Konya, Turkey, 42131
        • Selçuk University School of Medicine
      • Samsun, Turkey, 55139
        • Ondokuz Mayıs University School of Medicine
      • Trabzon, Turkey, 61080
        • Karadeniz Technical University School of Medicine
    • Istanbul Province
      • Istanbul, Istanbul Province, Turkey, 34098
        • Istanbul University Cerrahpaşa School of Medicine
  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85006
        • Banner Health Good Samaritan
      • Phoenix, Arizona, United States, 85013
        • Dignity Health - St. Joseph's Hospital
    • California
      • Garden Grove, California, United States, 92843
        • Advanced Rx Clinical Research
      • Lancaster, California, United States, 93534
        • High Desert Gastroenterology
      • Los Angeles, California, United States, 90027
        • Kaiser Permanente Los Angeles Medical Center
      • Palo Alto, California, United States, 94304
        • Stanford University Medical Center
      • Rialto, California, United States, 92377
        • Inland Empire Liver Foundation
      • San Diego, California, United States, 92154
        • Kaiser Permanente
      • San Francisco, California, United States, 94115
        • Kaiser Foundation Hospital
      • San Jose, California, United States, 95116
        • San Jose Gastroenterology
      • Torrance, California, United States, 90505
        • South Bay Gastroenterology Medical Group
    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Yale University School of Medicine
    • Florida
      • Miami, Florida, United States, 33136
        • Schiff Center for Liver Disease
    • Georgia
      • Atlanta, Georgia, United States, 30309
        • Digestive Healthcare of Georgia
      • Marietta, Georgia, United States, 30060
        • Gastrointestinal Specialists of Georgia
    • Maryland
      • Baltimore, Maryland, United States, 21202
        • Mercy Medical Center
      • Catonsville, Maryland, United States, 21228
        • Digestive Disease Associates, PA
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Beth Israel Deaconess Medical Center
      • Newton, Massachusetts, United States, 02462
        • Newton-Wellesley Hospital
      • Springfield, Massachusetts, United States, 01105-1406
        • The Research Institute
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Henry Ford Health System
    • New Jersey
      • Newark, New Jersey, United States, 07103
        • University of Medicine and Dentistry of New Jersey
    • New York
      • Flushing, New York, United States, 11355
        • Sing Chan, MD
      • Manhasset, New York, United States, 11030
        • North Shore University Hospital
    • North Carolina
      • Charlotte, North Carolina, United States, 28204
        • Carolinas Healthcare System
      • Statesville, North Carolina, United States, 28677
        • Piedmont Healthcare
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73112
        • Integris Baptist Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19140
        • Temple University Hospital
      • Philadelphia, Pennsylvania, United States, 19141
        • Einstein Healthcare Network
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • Rhode Island Hospital
    • Tennessee
      • Nashville, Tennessee, United States, 37205
        • Nashville Medical Research Institute
    • Texas
      • Austin, Texas, United States, 78756
        • Austin Center for Clinical Research
      • Houston, Texas, United States, 77005
        • Kelsey Research Foundation
      • Houston, Texas, United States, 77030
        • Liver Associates of Texas
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • University of Utah School of Medicine
    • Virginia
      • Norfolk, Virginia, United States, 23502
        • Digestive and Liver Disease Specialists
    • Washington
      • Seattle, Washington, United States, 98104
        • Harborview Medical Center
    • Wisconsin
      • Madison, Wisconsin, United States, 53705
        • University of Wisconsin Hospital and Clinics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Treatment naïve men and women ≥18 years of age with chronic HBV infection initiating entecavir or tenofovir treatment.

Description

Inclusion Criteria:

  • The subject is chronically infected with HBV.The subject is treatment naïve and is initiating HBV antiviral therapy with either entecavir or tenofovir as indicated in the FDA approved label
  • The subject will be considered treatment naïve if he/she had <12 weeks of oral antiviral therapy with any nucleoside or nucleotide therapy
  • The subject is at least 18 years of age at the time of enrollment
  • Adequate medical records are available for collection of protocol-defined demographics, baseline patient characteristics, medical history, virology and specific laboratory results, and other information to verify enrollment criteria
  • The subject and/or legally authorized representative is willing and able to provide consent prior to providing a specimen(s)

Exclusion Criteria:

  • Subject is in one of the following patient populations:

    • Acute HBV infection
    • Patients who are HBV immune tolerant
    • Human immunodeficiency virus (HIV) and/or hepatitis C virus (HCV) co-infection
    • Solid organ or bone marrow transplant recipients
    • Renal failure or dialysis
    • Evidence or history of hepatic decompensation
    • Evidence or history of hepatocellular carcinoma
  • Underlying liver disease other than HBV
  • Receiving chemotherapy, immunosuppressive agents
  • Subject is unsuitable for study participation based on the Investigator's decision (eg, unlikely to comply with study visit schedule, significant medical complication)
  • Participating in another investigational study that the Investigator believes might interfere with the subject's participation in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
study population

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Association between virologic response at Week 12 (assessed using the Aptima HBV Quant assay) and virologic response at Week 48 (assessed using an FDA-approved HBV quant assay).
Time Frame: Week 48 (from start of therapy)

Virologic response is defined as HBV DNA levels less than the lower limit of quantitation at the assessed time point.

Association will be measured as an odds ratio.
Week 48 (from start of therapy)
Association between virologic response at Week 24 (assessed using the Aptima HBV Quant assay) and virologic response at Week 48 (assessed using an FDA-approved HBV quant assay).
Time Frame: Week 48 (from start of therapy)

Virologic response is defined as HBV DNA levels less than the lower limit of quantitation at the assessed time point.

Association will be measured as an odds ratio.
Week 48 (from start of therapy)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hologic, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Christine Kuslich, Hologic, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2014

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 23, 2018

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 12, 2014

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 16, 2014

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 18, 2014

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 1, 2018

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 31, 2018

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • V10434-HBVQPS-CSP-01 (Other Identifier: Hologic)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis B, Chronic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings